These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 36731437)

  • 1. Experience of Subcutaneous Levetiracetam in Palliative Care.
    Gaviria-Carrillo M; Mora-Muñoz L; Diaz-Forero AF; Vargas-Osorio J; Torres-Ballesteros V; Estrada J; Vélez Van Meerbeke A; Rodríguez JH
    Med Princ Pract; 2023; 32(1):90-95. PubMed ID: 36731437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subcutaneous Levetiracetam and Sodium Valproate Use in Palliative Care Patients.
    Kondasinghe JS; Look ML; Moffat P; Bradley K
    J Pain Palliat Care Pharmacother; 2022 Dec; 36(4):228-232. PubMed ID: 35930500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subcutaneous levetiracetam for the management of seizures at the end of life.
    Sutherland AE; Curtin J; Bradley V; Bush O; Presswood M; Hedges V; Naessens K
    BMJ Support Palliat Care; 2018 Jun; 8(2):129-135. PubMed ID: 28735270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Continuous subcutaneous use of levetiracetam: a retrospective review of tolerability and clinical effects.
    Rémi C; Lorenzl S; Vyhnalek B; Rastorfer K; Feddersen B
    J Pain Palliat Care Pharmacother; 2014 Dec; 28(4):371-7. PubMed ID: 25313924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subcutaneous Levetiracetam for the Management of Seizures at the End of Life: An Audit and Updated Literature Review.
    Sutherland A; Meldon C; Harrison T; Miller M
    J Palliat Med; 2021 Jul; 24(7):976-981. PubMed ID: 33296254
    [No Abstract]   [Full Text] [Related]  

  • 6. Levetiracetam add-on for drug-resistant localization related (partial) epilepsy.
    Chaisewikul R; Privitera MD; Hutton JL; Marson AG
    Cochrane Database Syst Rev; 2001; (1):CD001901. PubMed ID: 11279737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Add-on levetiracetam in children and adolescents with refractory epilepsy: results of an open-label multi-centre study.
    Callenbach PM; Arts WF; ten Houten R; Augustijn P; Gunning WB; Peeters EA; Weber AM; Stroink H; Geerts Y; Geerts AT; Brouwer OF
    Eur J Paediatr Neurol; 2008 Jul; 12(4):321-7. PubMed ID: 17950011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spotlight on levetiracetam in epilepsy.
    Lyseng-Williamson KA
    CNS Drugs; 2011 Oct; 25(10):901-5. PubMed ID: 21936590
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Continuous subcutaneous levetiracetam in the management of seizures at the end of life: a case report.
    Wells GH; Mason LD; Foreman E; Chambers J
    Age Ageing; 2016 Mar; 45(2):321-2. PubMed ID: 26744359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Levetiracetam. A review of its adjunctive use in the management of partial onset seizures.
    Dooley M; Plosker GL
    Drugs; 2000 Oct; 60(4):871-93. PubMed ID: 11085199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term levetiracetam treatment in patients with epilepsy: 3-year follow up.
    Kuba R; Novotná I; Brázdil M; Kocvarová J; Tyrlíková I; Mastík J; Rektor I
    Acta Neurol Scand; 2010 Feb; 121(2):83-8. PubMed ID: 20003081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy and tolerability of levetiracetam in pharmacoresistant epileptic dogs.
    Volk HA; Matiasek LA; Luján Feliu-Pascual A; Platt SR; Chandler KE
    Vet J; 2008 Jun; 176(3):310-9. PubMed ID: 17468024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of Subcutaneous Levetiracetam in Palliative Care Patients.
    Papa P; Oricchio F; Ginés M; Maldonado C; Tashjian A; Ibarra M; Percovich M; Fagiolino P; Pedragosa B; Vázquez M
    J Palliat Med; 2021 Feb; 24(2):248-251. PubMed ID: 32267792
    [No Abstract]   [Full Text] [Related]  

  • 14. An open-label study of levetiracetam at individualised doses between 1000 and 3000 mg day(-1) in adult patients with refractory epilepsy.
    Abou-Khalil B; Hemdal P; Privitera MD
    Seizure; 2003 Apr; 12(3):141-9. PubMed ID: 12651078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and tolerability of levetiracetam during 1-year follow-up in patients with refractory epilepsy.
    Ben-Menachem E; Gilland E
    Seizure; 2003 Apr; 12(3):131-5. PubMed ID: 12651076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Continuous subcutaneous levetiracetam in end-of-life care.
    Furtado I; Gonçalves F; Gonçalves J; Neves J
    BMJ Case Rep; 2018 Jan; 2018():. PubMed ID: 29351934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Experience with levetiracetam in childhood epilepsy].
    Neuwirth M; Saracz J; Hegyi M; Paraicz E; Kollár K; Móser J; Rosdy B; Herczegfalvi A; Fogarasi A
    Ideggyogy Sz; 2006 May; 59(5-6):179-82. PubMed ID: 16786712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of levetiracetam as an add-on therapy in children aged less than 4 years with refractory epilepsy.
    Li S; Cao J; Xiao N; Cai F
    J Child Neurol; 2010 May; 25(5):609-13. PubMed ID: 19779208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Levetiracetam Versus Phenytoin for Seizure Prophylaxis Following Traumatic Brain Injury: A Systematic Review and Meta-Analysis.
    Yang Y; Zheng F; Xu X; Wang X
    CNS Drugs; 2016 Aug; 30(8):677-88. PubMed ID: 27395404
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pregabalin add-on for drug-resistant focal epilepsy.
    Panebianco M; Bresnahan R; Hemming K; Marson AG
    Cochrane Database Syst Rev; 2019 Jul; 7(7):CD005612. PubMed ID: 31287157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.